Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01653470 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

A Phase 1 study of Cancer, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
141
Enrollment target
5
Study locations

NCT01653470 is a Phase 1 study of Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 141 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01653470, a Phase 1 study of Cancer, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
141 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors

Conditions Studied

Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Leucovorin
  • DRUG Paclitaxel
  • DRUG Irinotecan
  • DRUG 5-Fluorouracil (5FU)

Study Locations (5)

California

  • Usc/Norris Comprehensive Cancer Center - Los Angeles

Other

  • Local Institution - Brussels

Alberta

  • Local Institution - Edmonton

Ontario

  • Local Institution - Toronto

Quebec

  • Local Institution - Ottawa

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2012-10-12
Est. Completion 2017-05-08
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01653470

The ClinicalTrials.gov registry entry for NCT01653470 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01653470 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Other, Alberta.

Frequently Asked Questions

What is clinical trial NCT01653470 about?

NCT01653470 is a clinical study titled "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors". The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors

What is the current status of trial NCT01653470?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2012-10-12. Estimated completion is 2017-05-08.

What conditions does trial NCT01653470 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT01653470?

The interventions under investigation include: Carboplatin (DRUG), Leucovorin (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG), 5-Fluorouracil (5FU) (DRUG).

Who is sponsoring clinical trial NCT01653470?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01653470 being conducted?

This trial has 5 study locations across California, Alberta, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.